Rheumatic Musculoskeletal Diseases and COVID-19 A Review of the First 6 Months of the Pandemic

Frontiers in Medicine

article

Martin H. Stradner¹  Christian Dejaco²  Jochen Zwerina³  Ruth D. Fritsch-Stork⁴ 

[1] Department of Rheumatology and Immunology, Medical University of Graz;Department of Rheumatology, Hospital of Brunico (SABES-ASDAA);Trauma Centre Meidling, Ludwig Boltzmann Institute of Osteology at Hanusch Hospital of Oesterreichische Gesundheitskassa and Allgemeine Unfallversicherungsanstalt, First Medical Department Hanusch Hospital;Medical Faculty, Sigmund Freud Private University

关键词: COVID-19;    SARS-CoV-2;    rheumatic and musculoskeletal disease;    rheumatoid arthritis;    systemic lupus erythematosus;    Kawasaki disease;    hydroxychloroquine;    IL-6;   

DOI  :  10.3389/fmed.2020.562142

学科分类：社会科学、人文和艺术（综合）

来源: Frontiers

【 摘 要 】

In December 2019, a cluster of severe pneumonia was observed in China, with the subsequent discovery of a new beta-coronavirus (SARS-CoV-2) as the causative agent. The elicited disease COVID-19 is characterized by fever, dry cough, myalgia, or fatigue and has a favorable outcome in the majority of cases. However, in some patients COVID-19 leads to severe pneumonia and sepsis with subsequent respiratory failure and gastrointestinal, hematological, neurological, and cardiovascular complications. A higher risk of infection is intrinsic to active rheumatic and musculoskeletal diseases (RMD) and the use of biological disease modifying anti-rheumatic drugs (DMARDs). With an increasing number of reports on COVID-19 in RMD patients, we are beginning to appraise their risks. In this review, we summarize the published cases of COVID-19 infections in RMD patients, including patients with inflammatory arthritis and connective tissue diseases as well as anti-phospholipid syndrome and Kawasaki syndrome. Overall, patients with inflammatory arthritis do not seem to be at a higher risk for infection or a severe course of COVID-19. Risk for critical COVID-19 in patients with systemic inflammatory diseases such as SLE or vasculitis might be increased, but this needs further confirmation. Furthermore, we summarize the data on DMARDs used to fight SARS-CoV-2 infection and hyperinflammation.

【 授权许可】

CC BY